KRAS and cancer: Previous studies have also confirmed this finding, demonstrating that oncogenic KRAS inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression in colorectal cell lines.52 Oncogenic activation of RAS is also well known to reduce the expression of antigen-presenting MHC on cancer cells, and such downregulation results in decreased immunogenicity of the RAS-transformed cells, thus enabling the cells to evade the immune response.30 This finding may have implications for selecting patients who will benefit from immunotherapy.